Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Wilson HTM Rapid Insights Investor Conference 2016
11 slides from Mayne Pharma's conference presentation, Jun 2, 2016
Slide 1: Mayne Pharma Group Limited – Wilson HTM Rapid Insights Investor Conference
For personal use only Mayne Pharma Group Limited Wilson HTM Rapid Insights Investor Conference 2 June 2016
Slide 2: Mayne Pharma overview
Mayne Pharma overview For personal use only ● Australian-listed specialty pharmaceutical company, Revenue by geography (1H16) headquartered in Adelaide 10%2% USA ● Develops and manufactures generic and proprietary Australia pharmaceuticals which are distributed globally either Rest of World directly
Slide 3: Mayne Pharma business segments & financials
Mayne Pharma business segments & financials United States Rest of world For personal use only Generic Products (GPD) Specialty Brands (SBD) Metrics Contract Services (MCS) Mayne Pharma International (MPI) Description Develops, manufactures, Markets and distributes specialty Provides contract Develop
Slide 4: Mayne Pharma's international footprint
Mayne Pharma’s international footprint For personal use only US Commercial Office Raleigh, North Carolina Product development, manufacturing and Distribution facility, Greenville, Global North Carolina Commercial 36.1 acre facility; 99,200ft2 of Office manufacturing space. Melbourne, FDA approved. T
Slide 5: Investing for growth – Greenville, NC site expansion
Investing for growth – Greenville, NC site expansion For personal use only Construction status as at May 2016 ● New 125,000ft2 oral solid dose manufacturing facility construction commenced October 2015 ● Commercial production to migrate to new building ● Product launches from scheduled for January 2
Slide 6: Investing for growth – research and development
Investing for growth – research and development For personal use only US Pipeline statistics – IMS market size (US$bn)1 ● Diverse capabilities 8.0 5.0 7.0 - Oral (tablets and capsules) 6.0 - Topical (ointments, solutions and powders) 4.0 1.7 - Potent compounds 2.0 0.3 - DEA controlled substances 0.0
Slide 7: FY16 key product highlights
FY16 key product highlights For personal use only Timing Event Country May 2016 Doryx™ MPC 60mg and 120mg tablets approved by FDA US Invested US$2.8m in Hedgepath Pharmaceuticals to support ongoing May 2016 clinical program using Mayne Pharma’s patented oral formulation of US itraconazole to treat c
Slide 8: Doryx update
Doryx update For personal use only Doryx weekly prescription (TRx) data Doryx franchise (50mg and 200mg) market share 6000 ~7% of the tetracycline addressable market1 5000 ― Solodyn TRx market share gain reflects 4000 inclusion of business previously not reported by IMS 3000 2000 Doryx MPC appro
Slide 9: Mayne Pharma has an experienced leadership team
Mayne Pharma has an experienced leadership team For personal use only Scott Richards Stefan Cross Chief Executive Officer President, Mayne Pharma USA Actavis, Hospira, FH Faulding & Co. Hospira, FH Faulding & Co Mark Cansdale Dr Ilana Stancovski Group CFO, Company Secretary Chief Scientific Officer
Slide 10: Significant opportunities to drive growth
Significant opportunities to drive growth For personal use only ● Optimize market penetration of product portfolio ● Approval and launch of filed FDA products 1. US retail generics ● Control manufacture, distribution and sales and marketing of key franchises maximization ● Efficient and reliable pro
Slide 11: A specialty pharmaceutical company with an increasingly diversified portfolio
A specialty pharmaceutical company with an increasingly diversified For personal use only portfolio of products, technologies and footprint 11
Mayne Pharma Group — Wilson HTM Rapid Insights Investor Conference 2016 on 6ix